Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis

Table 1 Effect of MK-AS on weight and inhibition of in situ HCC

Treatment group	Tumor weight(g)	Inhibition rate(%)
Saline	1.29 ± 0.13	-
MK-AS 100 mg/kg per day	0.44 ± 0.18b	65.89
MK-AS 50 mg/kg per day	0.64 ± 0.18b	50.39
MK-AS 25 mg/kg per day	0.70 ± 0.14b	45.74
MK-Sen 50 mg/kg per day	1.04 ± 0.14a	19.38

^aP < 0.05,

^bP < 0.01 vs control group.

Table 2 Effect of MK-AS on growth of in situ human HCC

Treatment group	Tumor volume (mm3)
Saline	807.75 ± 195.19
MK-AS 100 mg/kg per day	294.50 ± 70.66b
MK-AS 50 mg/kg per day	532.00 ± 121.57b
MK-AS 25 mg/kg per day	552.75 ± 84.38b
MK-Sen 50 mg/kg per day	630.88 ± 188.76a

^aP < 0.05,

^bP < 0.01 vs control group.